{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:07:14Z","timestamp":1790140034585,"version":"4.0.1"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genome Ed."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Chronic hepatitis B virus (HBV) infection remains a major global health problem and there is no curative treatment currently available. RNA-targeting CRISPR systems offer a potential alternative to DNA-editing nucleases by enabling direct degradation of viral transcripts without introducing genomic breaks. In this report, we evaluated the antiviral activity of synthetic guide RNA (gRNA)\/Cas13d ribonucleoproteins (RNPs) targeting HBV RNA and a combination use with DNA-targeting RNPs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We designed 10 gRNAs targeting conserved regions across the HBV transcriptome followed by screening for best candidate gRNA for Cas13d. To enhance antiviral efficacy, we evaluated multiplex RNA targeting using combined gRNA6+gRNA7\/Cas13d RNPs, and combined RNA-targeting gRNA7\/Cas13d with previously validated HBV DNA-targeting gRNA9\/Cas9 and gRNA4\/Cas12a RNPs for HBV treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Amongst these 10 gRNAs, gRNA7\/Cas13d exhibited selective knockdown of its specific target RNA transcript without inducing a broad suppression of total HBV DNA, mRNAs, and proteins. The antiviral effect of gRNA7\/Cas13d RNP was transient, diminishing by Day 3 post the treatment. The combined gRNA6+gRNA7\/Cas13d treatment also did not further induce global HBV suppression compared with single gRNAs, although gRNA7\/Cas13d still showed a robust target-specific RNA cleavage during the combined treatment in HBV cellular models. While gRNA9\/Cas9 and gRNA4\/Cas12a exhibited the dominant antiviral effects, either alone or in combination, leading to substantial reductions in HBV replication and expression, the addition of gRNA7\/Cas13d further enhanced the suppression of the gRNA7-specific HBV RNA transcript, achieving up to an 80% reduction in the target RNA level.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Collectively, these findings demonstrate that gRNA7\/Cas13d can mediate target-specific HBV RNA cleavage but has limited overall antiviral activity when used alone as a single-agent; however, the combination of DNA- and RNA-targeting CRISPR-RNPs may provide a complementary approach for enhancing target-specific HBV RNA suppression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fgeed.2026.1824895","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:42:51Z","timestamp":1790138571000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Combined RNA- and DNA-targeting CRISPR ribonucleoproteins enhance suppression of HBV transcripts"],"prefix":"10.3389","volume":"8","author":[{"given":"Puja","family":"Banik","sequence":"first","affiliation":[{"name":"Center of Excellence in Inflammation, Infectious Disease and Immunity, James H. Quillen College of Medicine, East Tennessee State University","place":["Johnson, TN, United States"]},{"name":"Department of Internal Medicine, Division of Infectious, Inflammatory and Immunologic Diseases, Quillen College of Medicine, ETSU","place":["Johnson, TN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Addison C.","family":"Hill","sequence":"additional","affiliation":[{"name":"Center of Excellence in Inflammation, Infectious Disease and Immunity, James H. Quillen College of Medicine, East Tennessee State University","place":["Johnson, TN, United States"]},{"name":"Department of Internal Medicine, Division of Infectious, Inflammatory and Immunologic Diseases, Quillen College of Medicine, ETSU","place":["Johnson, TN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison B.","family":"Schank","sequence":"additional","affiliation":[{"name":"Center of Excellence in Inflammation, Infectious Disease and Immunity, James H. Quillen College of Medicine, East Tennessee State University","place":["Johnson, TN, United States"]},{"name":"Department of Internal Medicine, Division of Infectious, Inflammatory and Immunologic Diseases, Quillen College of Medicine, ETSU","place":["Johnson, TN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Center of Excellence in Inflammation, Infectious Disease and Immunity, James H. Quillen College of Medicine, East Tennessee State University","place":["Johnson, TN, United States"]},{"name":"Department of Internal Medicine, Division of Infectious, Inflammatory and Immunologic Diseases, Quillen College of Medicine, ETSU","place":["Johnson, TN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Center of Excellence in Inflammation, Infectious Disease and Immunity, James H. Quillen College of Medicine, East Tennessee State University","place":["Johnson, TN, United States"]},{"name":"Department of Internal Medicine, Division of Infectious, Inflammatory and Immunologic Diseases, Quillen College of Medicine, ETSU","place":["Johnson, TN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaeden S.","family":"Pyburn","sequence":"additional","affiliation":[{"name":"Center of Excellence in Inflammation, Infectious Disease and Immunity, James H. Quillen College of Medicine, East Tennessee State University","place":["Johnson, TN, United States"]},{"name":"Department of Internal Medicine, Division of Infectious, Inflammatory and Immunologic Diseases, Quillen College of Medicine, ETSU","place":["Johnson, TN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Orfield","sequence":"additional","affiliation":[{"name":"Center of Excellence in Inflammation, Infectious Disease and Immunity, James H. Quillen College of Medicine, East Tennessee State University","place":["Johnson, TN, United States"]},{"name":"Department of Internal Medicine, Division of Infectious, Inflammatory and Immunologic Diseases, Quillen College of Medicine, ETSU","place":["Johnson, TN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuezu","family":"Wu","sequence":"additional","affiliation":[{"name":"Center of Excellence in Inflammation, Infectious Disease and Immunity, James H. Quillen College of Medicine, East Tennessee State University","place":["Johnson, TN, United States"]},{"name":"Department of Internal Medicine, Division of Infectious, Inflammatory and Immunologic Diseases, Quillen College of Medicine, ETSU","place":["Johnson, TN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad J.","family":"Hajipour","sequence":"additional","affiliation":[{"name":"Center of Excellence in Inflammation, Infectious Disease and Immunity, James H. Quillen College of Medicine, East Tennessee State University","place":["Johnson, TN, United States"]},{"name":"Department of Internal Medicine, Division of Infectious, Inflammatory and Immunologic Diseases, Quillen College of Medicine, ETSU","place":["Johnson, TN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"El Gazzar","sequence":"additional","affiliation":[{"name":"Center of Excellence in Inflammation, Infectious Disease and Immunity, James H. Quillen College of Medicine, East Tennessee State University","place":["Johnson, TN, United States"]},{"name":"Department of Internal Medicine, Division of Infectious, Inflammatory and Immunologic Diseases, Quillen College of Medicine, ETSU","place":["Johnson, TN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunbin","family":"Ning","sequence":"additional","affiliation":[{"name":"Center of Excellence in Inflammation, Infectious Disease and Immunity, James H. Quillen College of Medicine, East Tennessee State University","place":["Johnson, TN, United States"]},{"name":"Department of Internal Medicine, Division of Infectious, Inflammatory and Immunologic Diseases, Quillen College of Medicine, ETSU","place":["Johnson, TN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan P.","family":"Moorman","sequence":"additional","affiliation":[{"name":"Center of Excellence in Inflammation, Infectious Disease and Immunity, James H. Quillen College of Medicine, East Tennessee State University","place":["Johnson, TN, United States"]},{"name":"Department of Internal Medicine, Division of Infectious, Inflammatory and Immunologic Diseases, Quillen College of Medicine, ETSU","place":["Johnson, TN, United States"]},{"name":"Hepatitis (HCV\/HBV\/HIV) Program, James H. Quillen VA Medical Center, Department of Veterans Affairs","place":["Johnson, TN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi Q.","family":"Yao","sequence":"additional","affiliation":[{"name":"Center of Excellence in Inflammation, Infectious Disease and Immunity, James H. Quillen College of Medicine, East Tennessee State University","place":["Johnson, TN, United States"]},{"name":"Department of Internal Medicine, Division of Infectious, Inflammatory and Immunologic Diseases, Quillen College of Medicine, ETSU","place":["Johnson, TN, United States"]},{"name":"Hepatitis (HCV\/HBV\/HIV) Program, James H. Quillen VA Medical Center, Department of Veterans Affairs","place":["Johnson, TN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wang","sequence":"additional","affiliation":[{"name":"Center of Excellence in Inflammation, Infectious Disease and Immunity, James H. Quillen College of Medicine, East Tennessee State University","place":["Johnson, TN, United States"]},{"name":"Department of Internal Medicine, Division of Infectious, Inflammatory and Immunologic Diseases, Quillen College of Medicine, ETSU","place":["Johnson, TN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.antiviral.2015.06.008","article-title":"Chronic hepatitis B: virology, natural history, current management and a glimpse at future opportunities","volume":"121","author":"Gish","year":"2015","journal-title":"Antivir. Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.antiviral.2015.08.005","article-title":"Metabolism and function of hepatitis B virus cccDNA: implications for the development of cccDNA-targeting antiviral therapeutics","volume":"122","author":"Guo","year":"2015","journal-title":"Antivir. Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"866800","DOI":"10.3389\/fcell.2022.866800","article-title":"Cas13d: a new molecular scissor for transcriptome engineering","volume":"10","author":"Gupta","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"106326","DOI":"10.1016\/j.antiviral.2025.106326","article-title":"Suppression of HBV replication and expression by CRISPR\/Cas9 ribonucleoproteins","volume":"245","author":"Hill","year":"","journal-title":"Antivir. Res."},{"key":"B5","article-title":"Synthetic gRNA\/Cas12a RNP - a novel CRISPR therapeutic for HBV DNA disruption and viral suppression","author":"Hill","year":"","journal-title":"Gene Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"102278","DOI":"10.1016\/j.omtn.2024.102278","article-title":"Evaluation of the effect of RNA secondary structure on Cas13d-mediated target RNA cleavage","volume":"35","author":"Hussein","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41551-024-01277-5","article-title":"Large DNA deletions occur during DNA repair at 20-fold lower frequency for base editors and prime editors than for Cas9 nucleases","volume":"9","author":"Hwang","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"B8","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.cell.2018.02.033","article-title":"Transcriptome engineering with RNA-targeting type VI-D CRISPR effectors","volume":"173","author":"Konermann","year":"2018","journal-title":"Cell"},{"key":"B9","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nbt.4192","article-title":"Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements","volume":"36","author":"Kosicki","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.4254\/wjh.v7.i8.1030","article-title":"Current and future antiviral drug therapies of hepatitis B chronic infection","volume":"7","author":"Koumbi","year":"2015","journal-title":"World J. Hepatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41467-024-44738-w","article-title":"Massively parallel profiling of RNA-Targeting CRISPR-Cas13d","volume":"15","author":"Kuo","year":"2024","journal-title":"Nat. Commun"},{"key":"B12","doi-asserted-by":"publisher","first-page":"W171","DOI":"10.1093\/nar\/gkz365","article-title":"CHOPCHOP v3: expanding the CRISPR web toolbox beyond genome editing","volume":"47","author":"Labun","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.jhep.2024.05.025","article-title":"CRISPR-Cas13b-mediated suppression of HBV replication and protein expression","volume":"81","author":"Mccoullough","year":"2024","journal-title":"J. Hepatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.chembiol.2021.07.011","article-title":"Chemically modified guide RNAs enhance CRISPR-Cas13 knockdown in human cells","volume":"29","author":"M\u00e9ndez-Mancilla","year":"2022","journal-title":"Cell Chem. Biol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41593-022-01207-1","article-title":"An RNA-Targeting CRISPR-Cas13d system alleviates disease-related phenotypes in huntington's disease models","volume":"26","author":"Morelli","year":"2023","journal-title":"Nat. Neurosci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","article-title":"HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B","volume":"64","author":"Nassal","year":"2015","journal-title":"Gut"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.3390\/v13091850","article-title":"Efficient inhibition of HIV using CRISPR\/Cas13d nuclease system","volume":"13","author":"Nguyen","year":"2021","journal-title":"Viruses"},{"key":"B18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jhep.2016.08.013","article-title":"Time trends of chronic HBV infection over prior decades - a global analysis","volume":"66","author":"Ott","year":"2017","journal-title":"J. Hepatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"eabo7676","DOI":"10.1126\/sciadv.abo7676","article-title":"Comprehensive analysis and accurate quantification of unintended large gene modifications induced by CRISPR-Cas9 gene editing","volume":"8","author":"Park","year":"2022","journal-title":"Sci. Adv."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1073\/pnas.84.4.1005","article-title":"Production of hepatitis B virus particles in hep G2 cells transfected with cloned hepatitis B virus DNA","volume":"84","author":"Sells","year":"1987","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B22","doi-asserted-by":"publisher","first-page":"733364","DOI":"10.3389\/fimmu.2021.733364","article-title":"Interferon and Hepatitis B: current and future perspectives","volume":"12","author":"Ye","year":"2021","journal-title":"Front. Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1038\/s41467-022-30546-7","article-title":"Broad-spectrum CRISPR-Mediated inhibition of SARS-CoV-2 variants and endemic coronaviruses in vitro","volume":"13","author":"Zeng","year":"2022","journal-title":"Nat. Commun."},{"key":"B24","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.cell.2018.09.001","article-title":"Structural basis for the RNA-Guided ribonuclease activity of CRISPR-Cas13d","volume":"175","author":"Zhang","year":"2018","journal-title":"Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e28952","DOI":"10.1002\/jmv.28952","article-title":"Synthetic gRNA\/Cas9 ribonucleoprotein targeting HBV DNA inhibits viral replication","volume":"95","author":"Zhang","year":"2023","journal-title":"J. Med. Virol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"258","DOI":"10.14218\/JCTH.2018.00054","article-title":"HBV cccDNA and its potential as a therapeutic target","volume":"7","author":"Zhu","year":"2019","journal-title":"J. Clin. Transl. Hepatol."}],"container-title":["Frontiers in Genome Editing"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgeed.2026.1824895\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:42:58Z","timestamp":1790138578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgeed.2026.1824895\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":26,"alternative-id":["10.3389\/fgeed.2026.1824895"],"URL":"https:\/\/doi.org\/10.3389\/fgeed.2026.1824895","relation":{},"ISSN":["2673-3439"],"issn-type":[{"value":"2673-3439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"article-number":"1824895"}}